Published in TB and Outbreaks Week, August 19th, 2003
The Intercept Blood System for platelets, approved for commercial use in Europe, is a blood safety technology that protects patients by reducing the risk of transfusion-transmitted diseases. Cerus is developing the Intercept Blood System for use with platelets, plasma, and red blood cells in collaboration with subsidiaries of Baxter International, Inc.
"We are pleased to report these inactivation results as the launch of Intercept platelets gets...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.